Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Akari Therapeutics PLC
AKTXCurrent price
1.26 USD
-0.017 USD (-1.31%)
Last closed
1.32 USD
Company
www.akaritx.com
ISIN
US00972G1085
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
38 116 980 USD
Yield for 12 month
-16.89 %
1Y
3Y
5Y
10Y
15Y
AKTX
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) and a novel discovery engine. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. In addition, its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. Further, the company develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts. Address: 22 Boston Wharf Road, Boston, MA, United States, 02210
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
80.00 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
–
Last Year
-4 000 USD
Current Quarter
–
Last Quarter
–
Key Figures AKTX
1 year
3 years
5 years
10 years
EBITDA
-14 178 500 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-32.99 %
PEG Ratio
–
Return On Equity TTM
-197.11 %
Wall Street Target Price
80.00 USD
Revenue TTM
–
Book Value
0.80 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
–
Diluted Eps TTM
–
Most Recent Quarter
I 2025
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics AKTX
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History AKTX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:20
Payout Ratio TTM
–
Last Split Date
17.08.2023
Stock Valuation AKTX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-0.064
Price Book MRQ
1.71
Financials AKTX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators AKTX
For 52 weeks
0.85 USD
4.40 USD
50 Day MA
1.25 USD
Shares Short Prior Month
76 994
200 Day MA
1.91 USD
Short Ratio
3.81
Shares Short
110 565
Short Percent
0.64 %
BeatStart